All In Biotech

Drug Trial Radar · NCT03554109

QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine

An Open-Label Randomized Phase 2 Trial Of The NANT NEOADJUVANT Triple-Negative Breast Cancer (TNBC) VACCINE VS Standard-Of-Care For The Neoadjuvant Treatment Of Subjects With TNBC

Last checked: Nov 20, 2026Latest source record: Feb 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Sep 2018

Primary completion

Jun 2020

Study completion Feb 9, 2022

Sponsor

Lead sponsor
ImmunityBio, Inc.Industry
Sponsor type
Industry
First posted
Jun 12, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized open-label phase 2 study to evaluate the efficacy and safety (as assessed by pCR) of the NANT Neoadjuvant TNBC Vaccine regimen (experimental arm) compared to the SoC dose-dense regimen of doxorubicin/cyclophosphamide followed by paclitaxel (control arm).

Conditions

  • Triple Negative Breast Cancer (TNBC)

Interventions

  • LeucovorinDrug

    L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt

  • 5-FluorouracilDrug

    5-fluoro-2,4 (1H,3H)-pyrimidinedione

  • Aldoxorubicin HClDrug

    albumin-binding prodrug of doxorubicin HCl

  • nab-PaclitaxelDrug

    Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin

  • ETBX-011Biological

    Ad5 \[E1-, E2b-\]-CEA

  • ETBX-051Biological

    Ad5 \[E1-, E2b-\]-Brachyury vaccine

  • ETBX-061Biological

    Ad5 \[E1-, E2b-\]-mucin 1\[MUC1\]

  • GI-4000Biological

    Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins

  • GI-6207Biological

    CEA yeast vaccine

  • GI-6301Biological

    Brachyury yeast vaccine

  • AvelumabDrug

    Avelumab

  • ALT-803Biological

    Recombinant human super agonist interleukin-15 (IL-15) complex

  • haNKBiological

    NK-92 \[CD16.158V, ER IL-2\]

  • CyclophosphamideDrug

    2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate

  • Doxorubicin HCLDrug

    Doxorubicin HCL

  • paclitaxelDrug

    paclitaxel

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pathological Complete Response RateTime frame: 8 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chan Soon-Shiong Institute for Medicine

    El Segundo, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.